265 related articles for article (PubMed ID: 27161178)
1. Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years.
Boustani MA; Pittman I; Yu M; Thieu VT; Varnado OJ; Juneja R
Diabetes Obes Metab; 2016 Aug; 18(8):820-8. PubMed ID: 27161178
[TBL] [Abstract][Full Text] [Related]
2. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
Gallwitz B; Dagogo-Jack S; Thieu V; Garcia-Perez LE; Pavo I; Yu M; Robertson KE; Zhang N; Giorgino F
Diabetes Obes Metab; 2018 Feb; 20(2):409-418. PubMed ID: 28817231
[TBL] [Abstract][Full Text] [Related]
3. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
Dungan KM; Weitgasser R; Perez Manghi F; Pintilei E; Fahrbach JL; Jiang HH; Shell J; Robertson KE
Diabetes Obes Metab; 2016 May; 18(5):475-82. PubMed ID: 26799540
[TBL] [Abstract][Full Text] [Related]
4. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z
Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
[TBL] [Abstract][Full Text] [Related]
5. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Tuttle KR; Lakshmanan MC; Rayner B; Busch RS; Zimmermann AG; Woodward DB; Botros FT
Lancet Diabetes Endocrinol; 2018 Aug; 6(8):605-617. PubMed ID: 29910024
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes.
Kaneko S; Oura T; Matsui A; Shingaki T; Takeuchi M
Endocr J; 2017 Dec; 64(12):1165-1172. PubMed ID: 28904247
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study.
Araki E; Inagaki N; Tanizawa Y; Oura T; Takeuchi M; Imaoka T
Diabetes Obes Metab; 2015 Oct; 17(10):994-1002. PubMed ID: 26179754
[TBL] [Abstract][Full Text] [Related]
9. Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes.
Onishi Y; Oura T; Nishiyama H; Ohyama S; Takeuchi M; Iwamoto N
Endocr J; 2016; 63(3):263-73. PubMed ID: 26698689
[TBL] [Abstract][Full Text] [Related]
10. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Dungan KM; Povedano ST; Forst T; González JG; Atisso C; Sealls W; Fahrbach JL
Lancet; 2014 Oct; 384(9951):1349-57. PubMed ID: 25018121
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
Yabe D; Nakamura J; Kaneto H; Deenadayalan S; Navarria A; Gislum M; Inagaki N;
Lancet Diabetes Endocrinol; 2020 May; 8(5):392-406. PubMed ID: 32333876
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): A randomized, double-blind, placebo-controlled, phase III trial.
Wang W; Yan X; Cheng Z; Zhang Q; Wang R; Deng Y; Ma J; Zhu D
Diabetes Obes Metab; 2023 Dec; 25(12):3690-3699. PubMed ID: 37732487
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post-hoc analyses of a randomized, double-blind, phase III study.
Shi LX; Liu XM; Shi YQ; Li QM; Ma JH; Li YB; Du LY; Wang F; Chen LL
J Diabetes Investig; 2020 Jan; 11(1):142-150. PubMed ID: 31102326
[TBL] [Abstract][Full Text] [Related]
14. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
Ludvik B; Frías JP; Tinahones FJ; Wainstein J; Jiang H; Robertson KE; García-Pérez LE; Woodward DB; Milicevic Z
Lancet Diabetes Endocrinol; 2018 May; 6(5):370-381. PubMed ID: 29483060
[TBL] [Abstract][Full Text] [Related]
15. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.
Terauchi Y; Satoi Y; Takeuchi M; Imaoka T
Endocr J; 2014; 61(10):949-59. PubMed ID: 25029955
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial.
Chen YH; Huang CN; Cho YM; Li P; Gu L; Wang F; Yang J; Wang WQ
Diabetes Obes Metab; 2018 Sep; 20(9):2121-2130. PubMed ID: 29708650
[TBL] [Abstract][Full Text] [Related]
17. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study.
Odawara M; Miyagawa J; Iwamoto N; Takita Y; Imaoka T; Takamura T
Diabetes Obes Metab; 2016 Mar; 18(3):249-57. PubMed ID: 26661514
[TBL] [Abstract][Full Text] [Related]
18. Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration.
Pantalone KM; Patel H; Yu M; Fernández Landó L
Diabetes Obes Metab; 2018 Jun; 20(6):1461-1469. PubMed ID: 29430801
[TBL] [Abstract][Full Text] [Related]
19. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States.
Mody R; Huang Q; Yu M; Zhao R; Patel H; Grabner M; Landó LF
Diabetes Obes Metab; 2019 Apr; 21(4):920-929. PubMed ID: 30520248
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes.
Berra CC; Resi V; Mirani M; Folini L; Rossi A; Solerte SB; Fiorina P
Pharmacol Res; 2020 Sep; 159():104996. PubMed ID: 32574827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
